臨床整形外科49巻3号

2014年03月発行

誌上シンポジウム 良性腫瘍に対する最新の治療戦略

線維性骨異形成

著者： 阿江啓介¹ 松本誠一¹ 下地尚¹ 谷澤泰介¹ 五木田茶舞¹ 澤村千草¹ 早川景子¹ 川口智義¹

所属機関： ¹がん研有明病院整形外科

ページ範囲：P.249 - P.260

　線維性骨異形成は，治療開始の年齢や発生部位がさまざまであり，また根治的な治療が困難な症例があるなど多様な病態を呈するため，各病態に合った治療法を適切に選択すべき疾患である．治療法の適応は，罹患部位によって大きく異なっていた．非骨折症例で手術を要する条件として，1．成長期の大腿骨，脛骨の変形　2．年齢にかかわらず痛みが持続する症例，特に大腿骨，脛骨，上腕骨，3．非典型的画像所見や経過，症状を呈する症例が挙げられた．

参考文献

1) Bianco P, Riminucci M, Majolagbe A, et al:Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 15:120-128, 2000

2) Campanacci M, Bertoni F, Capanna R:Malignant degeneration in fibrous dysplasia (presentation of 6 cases and review of the literature). Ital J Orthop Traumatol 15:373-381, 1979

3) Cohen MM Jr, Howell RE:Etiology of fibrous dysplasia and McCune-Albright syndrome. Int J Oral Maxillofac Surg 28:366-371, 1999

4) DiCaprio MR, Enneking WF:Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am 87:1848-1864, Review, 2005

5) Enneking WF, Gearen PF:Fibrous dysplasia of the femoral neck. Treatment by cortical bone-grafting. J Bone Joint Surg Am 68:1415-1422, 1986

6) Guille JT, Kumar SJ, MacEwen GD:Fibrous dysplasia of the proximal part of the femur. Long-term results of curettage and bone-grafting and mechanical realignment. J Bone Joint Surg Am 80:648-658, 1998

7) Hoshi M, Matsumoto S, Manabe J, et al:Malignant change secondary to fibrous dysplasia. Int J Clin Oncol 11:229-235, 2006

8) 古屋光太郎：Fibrous dysplasiaとその類似疾患．日整会誌43：151-174，1969

9) Ippolito E, Caterini R, Farsetti P, et al:Surgical treatment of fibrous dysplasia of bone in McCune-Albright syndrome. J Pediatr Endocrinol Metab 15 Suppl 3:939-944, 2002

10) Lane JM, Khan SN, O'Connor WJ, et al:Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res 382:6-12, 2001

11) Li GD, Ogose A, Hotta T, et al:Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia:A case report. Oncol Lett 2:1239-1242, 2011

12) Parisi MS, Oliveri B, Mautalen CA:Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 33:582-588, 2003

13) Plotkin H, Rauch F, Zeitlin L, et al:Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 88:4569-4575, 2003

14) Ruggieri P, Sim FH, Bond JR, et al:Malignancies in fibrous dysplasia. Cancer 73:1411-1424, 1994

15) Stanton RP, Ippolito E, Springfield D, et al:The surgical management of fibrous dysplasia of bone. Orphanet J Rare Dis 24;7 Suppl 1, 2012

16) US Food and Drug Administration. MedWatch:The FDA Safety Information and Adverse Event Reporting Program. Zometa (zoledronic acid) injection. www.fda.gov/safety/medwatch/Safetyinformation/SafetyAlertsforHumanMedicalProducts/ucm155619.htm (Accessed January 27, 2014)

17) World Health Organization Classification of Tumours. Fletcher CDM, Unni KK, Martens F. Pathology and Genetics Tumor of Soft Tissue and Bone. IARC Press, Lyon, 2002

18) Yang L, Jing Y, Hong D, et al:Valgus osteotomy combined with intramedullary nail for Shepherd's crook deformity in fibrous dysplasia:14 femurs with a minimum of 4 years follow-up. Arch Orthop Trauma Surg 130:497-502, 2010

19) Zacharin M, O'Sullivan M:Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 137:403-409, 2000

20) Zhang X, Shang X, Wang Y, et al:Intramedullary nailing for fibrous dysplasia of lower limbs. Oncol Lett 4:524-528, 2012．Epub 2012 Jun 11